Tranexamic Acid Reduce Blood Loss in Meningioma Resection

• Status: Not yet recruiting
• Trial end date: 2022-09-30
• Target enrollment: 0
• Participant gender: All

Summary

In neurosurgical setting, a large sample size trials of tranexamic acid (TXA) has been limited to TBI and SAH.

The evidence of TXA in brain tumor was scarce. A few case reports support the role of TXA in brain tumor patients with significant intraoperative bleeding and difficult achieving hemostasis. To prove the benefit of TXA for an attenuation of blood loss in brain tumor patients, research with a larger sample size is required. This prospective, randomized double-blind controlled study will be conducted to evaluate the effect of TXA in reducing blood loss and blood transfusion in patients with intracranial meningiomas, diameter > 5 cm in at least 2 dimensions from the latest radiographic findings.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chiang Mai University
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• The patients whose aged 18 to 60 years

• The patients who was diagnosed intracranial meningioma

• The radio-graphic finding of tumor diameter > 5 cm in at least 2 dimensions

• The patients have written informed consent

• The patients is scheduled for elective craniotomy to remove tumor

Exclusion Criteria:

• Patients who refuse to participate in this study

• Patients with recurrent tumor

• The patient is set operation for intracranial tissue biopsy

• The patients with history of TXA allergy

• The pregnant patients

• The patients with history of significant thromboembolic episode

• The patients with significant renal dysfunction (GFR ≤ 50 ml/min)